Alumis
ALMS
6.77
-0.16
-2.31%
Alumis
US · ALMS
#3337 by market cap
Listed 2024
6.77
-0.16
-2.31%
Live - 5344 symbols - heartbeat 266s ago
· 2026-10-08 09:18
Pre-market
6.88
+1.62%
After-hours
6.77
0.00%
Overnight
6.72
-0.74%
- Market cap
- 876.28M
- P/E (TTM)i
- -1.65
- P/Bi
- 1.94
- EPSi
- -2.86
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on ALMS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -1.18, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 4 years
Margins
- Operating margin
- -1,886.92%
- Net margin
- -1,011.75%
Key ratios & quality
- Altman Z-Scorei
- -1.18
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | -- | -- | 0 | 24.05M |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 12.55M | 20.50M | 35.20M | 91.86M |
| Research & development | 101.30M | 137.68M | 265.55M | 386.00M |
| Operating profit | -113.85M | -158.17M | -300.75M | -453.80M |
| Pretax profit | -111.93M | -154.99M | -294.23M | -251.89M |
| Tax | -- | -- | 0 | -8.56M |
| Net profit | -111.93M | -154.99M | -294.23M | -243.33M |
| Basic EPS | -3 | -3 | -10 | -3 |
| Diluted EPS | -2.91 | -2.99 | -10.38 | -2.86 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 17.39M | 2.67M | 2.07M | 1.93M | 1.74M | 1.66M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 22.30M | 34.45M | 19.52M | 15.59M | 18.61M | 23.36M |
| Research & development | 96.62M | 108.76M | 97.84M | 82.79M | 81.54M | 85.34M |
| Operating profit | -101.53M | -140.54M | -115.29M | -96.45M | -98.41M | -107.03M |
| Pretax profit | -98.96M | 50.76M | -110.75M | -92.93M | -93.05M | -143.98M |
| Tax | -- | -8.56M | 0 | 0 | -- | -1.76M |
| Net profit | -98.96M | 59.32M | -110.75M | -92.93M | -93.05M | -142.22M |
| Basic EPS | -2 | 1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -1.82 | 0.77 | -1.06 | -0.94 | -0.74 | -1.11 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 102.56M | 53.36M | 306.19M | 318.23M |
| Cash & ST investments | 92.87M | 48.95M | 288.26M | 308.50M |
| Inventory | -- | -- | -- | -- |
| Total assets | 108.17M | 89.61M | 340.99M | 411.94M |
| Total current liabilities | 13.35M | 20.87M | 50.91M | 73.32M |
| Short-term debt | 1.31M | 1.72M | 1.56M | 4.67M |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | 303,410,000.00 | 428,872,000.00 | 80,888,000.00 | 110,643,000.00 |
| Total equity | -195.24M | -339.26M | 260.10M | 301.30M |
| Retained earnings | -209.33M | -364.32M | -658.55M | -901.88M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 225.53M | 517.56M | 393.29M | 318.23M | 532.41M | 514.08M |
| Cash & ST investments | 208.75M | 486.32M | 377.72M | 308.50M | 522.94M | 502.29M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 261.30M | 610.93M | 488.01M | 411.94M | 671.59M | 560.62M |
| Total current liabilities | 60.45M | 85.58M | 65.42M | 73.32M | 70.90M | 76.23M |
| Short-term debt | 2.55M | 4.06M | 4.41M | 4.67M | 4.44M | 4.82M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 92,984,000.00 | 125,598,000.00 | 103,241,000.00 | 110,643,000.00 | 104,567,000.00 | 108,460,000.00 |
| Total equity | 168.31M | 485.33M | 384.77M | 301.30M | 567.02M | 452.16M |
| Retained earnings | -757.51M | -698.19M | -808.95M | -901.88M | -994.93M | -1.14B |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -107.72M | -129.98M | -255.08M | -369.52M |
| Depreciation & amortization | 250.00K | 1.28M | 3.15M | 3.50M |
| Free cash flow | -110.13M | -134.47M | -256.81M | -370.18M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 193.32M | 0 |
| Ending cash balance | 26.95M | 47.13M | 170.63M | 91.05M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -80.36M | -106.35M | -110.91M | -71.91M | -87.08M | -81.50M |
| Depreciation & amortization | 843.00K | 870.00K | 916.00K | 867.00K | 871.00K | 874.00K |
| Free cash flow | -80.39M | -106.97M | -110.91M | -71.91M | -87.25M | -81.74M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 749.00K | -749.00K | 0 | 323.80M | 1.57M |
| Ending cash balance | 129.71M | 153.50M | 66.63M | 91.05M | 65.27M | 65.09M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -86.69 |
| ROA %i | -103.48 | -156.73 | -136.66 | -64.63 |
| ROIC %i | -- | -- | -- | -81.72 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -1,886.92 |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | 7.68 | 2.56 | 6.01 | 4.34 |
| Quick ratioi | 6.99 | 2.38 | 5.70 | 4.24 |
| Debt / assetsi | 1.64 | 36.36 | 9.01 | 8.96 |
| LT debt / equityi | -- | -- | 11.21 | 10.70 |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -977.06 | -66.88 | -86.69 | -64.57 | -93.65 |
| ROA %i | -156.54 | -51.94 | -54.44 | -64.63 | -50.90 | -74.94 |
| ROIC %i | -- | -415.23 | -64.75 | -81.72 | -63.36 | -90.32 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -2,039.73 | -2,189.42 | -2,061.30 | -1,886.92 | -5,364.02 | -5,639.05 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.73 | 6.05 | 6.01 | 4.34 | 7.51 | 6.74 |
| Quick ratioi | 3.47 | 5.77 | 5.83 | 4.24 | 7.41 | 6.64 |
| Debt / assetsi | 12.20 | 6.35 | 7.75 | 8.96 | 5.31 | 6.50 |
| LT debt / equityi | 17.43 | 7.15 | 8.68 | 10.70 | 5.51 | 6.99 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Business of researching and developing medicines for autoimmune disorders100.00%
Quote time 2026-10-08 09:18:15 · For reference only, not investment advice and not tailored to your situation.